COMMUNIQUÉS West-GlobeNewswire

Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
07/10/2025
SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results [...]
Biomea Fusion Announces Pricing of Public Offering of Securities
07/10/2025
SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten [...]
Cannara obtient l’admissibilité à la DTC afin de faciliter l’accès des investisseurs américains et renforce son bilan grâce à la conversion de sa dette en actions
07/10/2025
MONTRÉAL, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0) , producteur verticalement intégré de cannabis [...]
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
07/10/2025
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
07/10/2025
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in [...]
Profusa Invests Additional $1 Million in Digital Treasury Assets
07/10/2025
BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Clover Health to Report Third Quarter 2025 Financial Results on November 4, 2025
07/10/2025
WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great [...]
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
07/10/2025
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for [...]
Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
07/10/2025
Strengthens Balance Sheet with Over $60 Million in Cash 1 , Excluding Bitcoin Treasury David Beckham Co-Founded IM8 on Track to Achieve $100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement [...]
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
07/10/2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc [...]
GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025
07/10/2025
Derisq delivers actionable insights about drug safety, efficacy and off-target risks prior to committing development capital BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging [...]
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
07/10/2025
MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic [...]
MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
07/10/2025
MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc [...]
Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
07/10/2025
Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing Achievement of Proven Long-Term Benefits WOBURN, Mass., Oct. 07, 2025 ( [...]
Privia Health to Report Third Quarter 2025 Results on Thursday, November 6
07/10/2025
ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, [...]
Parexel Expands Global Site Alliance Program, Delivering 40% Faster Site Activation, 20% Faster Study Start Up Timelines and Four Times More Patient Enrollments Per Site
07/10/2025
Parexel’s Site Alliance Program strengthens global partnerships with clinical research sites and reinforces leadership in site engagement excellence RALEIGH, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading [...]
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025
The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like [...]
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]

Pages